US 11,913,044 B2
Evolution of cytidine deaminases
David R. Liu, Cambridge, MA (US); and Tina Wang, Cambridge, MA (US)
Assigned to President and Fellows of Harvard College, Cambridge, MA (US); and The Broad Institute, Inc., Cambridge, MA (US)
Appl. No. 17/251,276
Filed by President and Fellows of Harvard College, Cambridge, MA (US); and The Broad Institute, Inc., Cambridge, MA (US)
PCT Filed Jun. 14, 2019, PCT No. PCT/US2019/037216
§ 371(c)(1), (2) Date Dec. 11, 2020,
PCT Pub. No. WO2019/241649, PCT Pub. Date Dec. 19, 2019.
Claims priority of provisional application 62/685,252, filed on Jun. 14, 2018.
Prior Publication US 2021/0261938 A1, Aug. 26, 2021
Int. Cl. C12N 9/22 (2006.01); C12N 9/78 (2006.01)
CPC C12N 9/78 (2013.01) [C12N 9/22 (2013.01); C12Y 305/04005 (2013.01)] 21 Claims
 
1. A cytidine deaminase protein variant comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 15 [rAPOBEC1], wherein the amino acid sequence of the cytidine deaminase protein variant includes at least three mutations at a position selected from the group consisting of R33, G45, N57, N65, Y75, T101, F113, A123, S149, A165, H166, T204, F205, and W224 of SEQ ID NO: 15 [rAPOBEC1], and wherein the cytidine deaminase protein variant has deaminase activity.